Subtopic Deep Dive

← Connective Tissue Growth Factor Research

CTGF in TGF-β Signaling
Research Guide

What is CTGF in TGF-β Signaling?

Connective Tissue Growth Factor (CTGF) acts as a downstream mediator of Transforming Growth Factor-β (TGF-β) signaling, promoting collagen synthesis and extracellular matrix production in fibroblasts during fibrosis.

CTGF expression increases in fibroblasts following TGF-β activation, driving pro-fibrotic responses (Duncan et al., 1999, 622 citations). Studies show CTGF mediates TGF-β-induced fibrosis in liver, skin, and heart tissues. Over 10 papers from 1999-2015 establish this pathway using knockout models and inhibitors.

Curated Papers

Key Challenges

Why It Matters

CTGF mediation of TGF-β signaling contributes to fibrosis in systemic sclerosis, liver cirrhosis, and cardiac hypertrophy, as shown in patient samples and animal models (Abou-Shady et al., 2000, 102 citations; Koitabashi et al., 2008, 98 citations). Targeting CTGF reduces collagen synthesis and myofibroblast differentiation, offering antifibrotic therapy potential in chronic heart failure and dystrophic muscle (Morales et al., 2013, 73 citations). Plasma CTGF levels serve as biomarkers for disease progression in these conditions.

Key Research Challenges

Dissecting CTGF-TGF-β Pathway Specificity

CTGF overlaps with other TGF-β effectors like PDGF, complicating isolation of its unique role in fibrosis (Frazier et al., 2000, 66 citations). Knockout models reveal compensatory mechanisms. Inhibitor studies struggle with off-target effects in vivo.

Translating Biomarkers to Therapies

Elevated plasma CTGF correlates with cardiac dysfunction but lacks causal validation for intervention (Koitabashi et al., 2008, 98 citations). Fibrosis reversibility post-CTGF inhibition remains unclear. Clinical trials need better patient stratification.

Cell-Type Specific Regulation

CTGF upregulation varies between fibroblasts, myocytes, and epithelial cells under TGF-β (Matsui, 2004, 79 citations; Cheng et al., 2015, 62 citations). Oxidative stress and AGEs modulate this in SSc and kidney models (Thuan et al., 2018, 107 citations). Single-cell profiling is needed.

Essential Papers

Connective tissue growth factor mediates transforming growth factor β‐induced collagen synthesis: down‐regulation by cAMP

Matthew R. Duncan, Ken Frazier, Susan Abramson et al. · 1999 · The FASEB Journal · 622 citations

ABSTRACT Connective tissue growth factor (CTGF) is a cysteine‐rich peptide synthesized and secreted by fibroblastic cells after activation with transforming growth factor beta (TGF‐β) that acts as ...

A Potential Link Between Oxidative Stress and Endothelial-to-Mesenchymal Transition in Systemic Sclerosis

Duong Thi Bich Thuan, Hatem Zayed, Ali H. Eid et al. · 2018 · Frontiers in Immunology · 107 citations

Systemic sclerosis (SSc), an autoimmune disease that is associated with a number of genetic and environmental risk factors, is characterized by progressive fibrosis and microvasculature damage in t...

Connective tissue growth factor in human liver cirrhosis

Mohamed Abou‐Shady, Helmut Friess, Arthur Zimmermann et al. · 2000 · Liver International · 102 citations

Abstract: Background: Connective tissue growth factor (CTGF) belongs to a family of factors that regulate fibrogenesis and wound healing. While the significance of transforming growth factor beta (...

Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure

Norimichi Koitabashi, Masashi Arai, Kazuo Niwano et al. · 2008 · European Journal of Heart Failure · 98 citations

Abstract Background: Connective tissue growth factor (CTGF) has been recently reported as a mediator of myocardial fibrosis; however, the significance of plasma CTGF concentration has not been eval...

Role of connective tissue growth factor and its interaction with basic fibroblast growth factor and macrophage chemoattractant protein‐1 in skin fibrosis

Sonoko Chujo, Fumiaki Shirasaki, Miki Kondo‐Miyazaki et al. · 2009 · Journal of Cellular Physiology · 83 citations

Abstract Activation of the immune system and abnormal growth of skin fibroblasts cause systemic sclerosis. Growth factors have various biological activities, including mediation of immune reactions...

Rapid upregulation of CTGF in cardiac myocytes by hypertrophic stimuli: implication for cardiac fibrosis and hypertrophy

Yoshio Matsui · 2004 · Journal of Molecular and Cellular Cardiology · 79 citations

Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2)

María Gabriela Morales, Daniel Cabrera, Carlos Céspedes et al. · 2013 · Cell and Tissue Research · 73 citations

Reading Guide

Foundational Papers

Start with Duncan et al. (1999, 622 citations) for core CTGF mediation mechanism in collagen synthesis; follow with Abou-Shady et al. (2000, 102 citations) for liver fibrosis context and Koitabashi et al. (2008, 98 citations) for biomarker evidence.

Recent Advances

Study Morales et al. (2013, 73 citations) for ACE inhibition effects and Cheng et al. (2015, 62 citations) for AGE-HMGB1 modulation; Thuan et al. (2018, 107 citations) covers SSc endothelial transition.

Core Methods

Core techniques include TGF-β stimulation assays with cAMP modulation (Duncan et al., 1999), immunohistochemistry in disease models (Abou-Shady et al., 2000), and plasma ELISA for biomarkers (Koitabashi et al., 2008).

How PapersFlow Helps You Research CTGF in TGF-β Signaling

Discover & Search

Research Agent uses searchPapers and citationGraph on Duncan et al. (1999) to map 622 citing papers, revealing CTGF-TGF-β links in fibrosis; exaSearch uncovers recent inhibitors, while findSimilarPapers extends to related CCN family mediators.

Analyze & Verify

Analysis Agent applies readPaperContent to extract TGF-β induction data from Duncan et al. (1999), then verifyResponse with CoVe checks claims against 10+ papers; runPythonAnalysis performs statistical correlation on CTGF expression datasets with GRADE scoring for evidence strength in fibrosis models.

Synthesize & Write

Synthesis Agent detects gaps in CTGF inhibitor trials via contradiction flagging across Morales et al. (2013) and Chujo et al. (2009); Writing Agent uses latexEditText, latexSyncCitations for pathway diagrams, and latexCompile to generate review manuscripts with exportMermaid for signaling flowcharts.

Use Cases

"Analyze CTGF expression datasets from TGF-β stimulated fibroblasts in Duncan 1999 and similar papers"

Research Agent → searchPapers('CTGF TGF-β fibroblasts') → Analysis Agent → runPythonAnalysis(pandas correlation on expression levels) → matplotlib plot of fold-changes vs. cAMP downregulation.

"Write LaTeX review on CTGF as TGF-β mediator in liver fibrosis citing Abou-Shady 2000"

Synthesis Agent → gap detection → Writing Agent → latexEditText(draft sections) → latexSyncCitations(10 papers) → latexCompile(PDF) with exportMermaid(TGF-β-CTGF pathway diagram).

"Find code for simulating CTGF-TGF-β signaling networks from related papers"

Research Agent → findSimilarPapers(Duncan 1999) → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect (SBML models of fibrosis pathways).

Automated Workflows

Deep Research workflow scans 50+ CTGF papers via citationGraph from Duncan et al. (1999), producing structured fibrosis reports with GRADE evidence tables. DeepScan applies 7-step CoVe to verify CTGF biomarker claims in Koitabashi et al. (2008). Theorizer generates hypotheses on CTGF inhibition in SSc from Thuan et al. (2018).

Try Doxa for CTGF in TGF-β Signaling Research

Frequently Asked Questions

What defines CTGF's role in TGF-β signaling?

CTGF serves as a downstream mediator, synthesized by fibroblasts post-TGF-β activation to drive collagen synthesis (Duncan et al., 1999, 622 citations).

What methods study CTGF-TGF-β interactions?

Researchers use cAMP downregulation assays, knockout models, and plasma quantification in fibroblasts, liver, and heart tissues (Duncan et al., 1999; Abou-Shady et al., 2000).

What are key papers on this topic?

Duncan et al. (1999, 622 citations) establishes mediation; Abou-Shady et al. (2000, 102 citations) links to liver cirrhosis; Koitabashi et al. (2008, 98 citations) validates cardiac biomarkers.

What open problems exist?

Specificity of CTGF vs. other mediators, translation of inhibitors to clinics, and cell-type regulation under stressors like oxidative damage remain unresolved (Thuan et al., 2018).